Stroke intervention pathways: NMDA receptors and beyond

Trends in Molecular Medicine

Volumn 17, Issue 5, 2011, Pages 266-275

  Lai, Ted Weita ^a,b   Shyu, Woei Cherng ^b   Wang, Yu Tian ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CALPAIN; CLATHRIN; DEATH ASSOCIATED PROTEIN KINASE; MEMANTINE; MITOGEN ACTIVATED PROTEIN KINASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEURONAL NITRIC OXIDE SYNTHASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; POSTSYNAPTIC DENSITY PROTEIN 95; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

BRAIN DAMAGE; BRAIN ISCHEMIA; CELL SURVIVAL; ENDOCYTOSIS; HUMAN; HUNTINGTON CHOREA; INTERVENTION STUDY; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; REVIEW; SIGNAL TRANSDUCTION; STROKE; SYNAPSE; UBIQUITINATION;

ANIMALS; CELL DEATH; CELL SURVIVAL; HUMANS; NEURONS; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION; STROKE;

EID: 79955645278     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2010.12.008     Document Type: Review

References (88)

1. Gladstone D.J., et al. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 2002, 33:2123-2136.
2. Dirnagl U., et al. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999, 22:391-397.
3. Lee J.M., et al. The changing landscape of ischaemic brain injury mechanisms. Nature 1999, 399:A7-14.
4. Rothman S.M., Olney J.W. Excitotoxicity and the NMDA receptor - still lethal after eight years. Trends Neurosci. 1995, 18:57-58.
5. Simon R.P., et al. Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. Science 1984, 226:850-852.
6. Wood P.L., Hawkinson J.E. N-methyl-D-aspartate antagonists for stroke and head trauma. Expert Opin. Investig. Drugs 1997, 6:389-397.
7. Traynelis S.F., et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol. Rev. 2010, 62:405-496.
8. Ryan T.J., et al. Evolution of NMDA receptor cytoplasmic interaction domains: implications for organisation of synaptic signalling complexes. BMC Neurosci. 2008, 9:6.
9. Collingridge G.L., et al. Long-term depression in the CNS. Nat. Rev. Neurosci. 2010, 11:459-473.
10. Ikonomidou C., et al. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 1999, 283:70-74.
11. Lipton S.A., Rosenberg P.A. Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med. 1994, 330:613-622.
12. Liu Y., et al. NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J. Neurosci. 2007, 27:2846-2857.
13. Chen M., et al. Differential roles of NMDA receptor subtypes in ischemic neuronal cell death and ischemic tolerance. Stroke 2008, 39:3042-3048.
14. Lu W., et al. Activation of synaptic NMDA receptors induces membrane insertion of new AMPA receptors and LTP in cultured hippocampal neurons. Neuron 2001, 29:243-254.
15. Leveille F., et al. Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors. FASEB J. 2008, 22:4258-4271.
16. Stanika R.I., et al. Coupling diverse routes of calcium entry to mitochondrial dysfunction and glutamate excitotoxicity. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:9854-9859.
17. Xu J., et al. Extrasynaptic NMDA receptors couple preferentially to excitotoxicity via calpain-mediated cleavage of STEP. J. Neurosci. 2009, 29:9330-9343.
18. Zhang S.J., et al. Decoding NMDA receptor signaling: identification of genomic programs specifying neuronal survival and death. Neuron 2007, 53:549-562.
19. Hardingham G.E., et al. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 2002, 5:405-414.
20. Hardingham G.E., Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat. Rev. Neurosci. 2010, 11:682-696.
21. Okamoto S., et al. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat. Med. 2009, 15:1407-1413.
22. Aluclu M.U., et al. Evaluation of effects of memantine on cerebral ischemia in rats. Neurosciences (Riyadh) 2008, 13:113-116.
23. Petralia R.S., et al. Organization of NMDA receptors at extrasynaptic locations. Neuroscience 2010, 167:68-87.
24. Sattler R., et al. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science 1999, 284:1845-1848.
25. Aarts M., et al. Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions. Science 2002, 298:846-850.
26. Christopherson K.S., et al. PSD-95 assembles a ternary complex with the N-methyl-D-aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain. J. Biol. Chem. 1999, 274:27467-27473.
27. Lai T.W., Wang Y.T. Fashioning drugs for stroke. Nat. Med. 2010, 16:1376-1378.
28. Zhou L., et al. Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95. Nat. Med. 2010, 16:1439-1443.
29. Tymianski M., et al. Source specificity of early calcium neurotoxicity in cultured embryonic spinal neurons. J. Neurosci. 1993, 13:2085-2104.
30. Tovar K.R., Westbrook G.L. The incorporation of NMDA receptors with a distinct subunit composition at nascent hippocampal synapses in vitro. J. Neurosci. 1999, 19:4180-4188.
31. Zhou M., Baudry M. Developmental changes in NMDA neurotoxicity reflect developmental changes in subunit composition of NMDA receptors. J. Neurosci. 2006, 26:2956-2963.
32. DeRidder M.N., et al. Traumatic mechanical injury to the hippocampus in vitro causes regional caspase-3 and calpain activation that is influenced by NMDA receptor subunit composition. Neurobiol. Dis. 2006, 22:165-176.
33. Terasaki Y., et al. Activation of NR2A receptors induces ischemic tolerance through CREB signaling. J. Cereb. Blood Flow Metab. 2010, 30:1441-1449.
34. Tu W., et al. DAPK1 interaction with NMDA receptor NR2B subunits mediates brain damage in stroke. Cell 2010, 140:222-234.
35. Lee F.J., et al. Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor. Cell 2002, 111:219-230.
36. Lopez-Menendez C., et al. Kidins220/ARMS downregulation by excitotoxic activation of NMDARs reveals its involvement in neuronal survival and death pathways. J. Cell Sci. 2009, 122:3554-3565.
37. Martin H.G., Wang Y.T. Blocking the deadly effects of the NMDA receptor in stroke. Cell 2010, 140:174-176.
38. Neyton J., Paoletti P. Relating NMDA receptor function to receptor subunit composition: limitations of the pharmacological approach. J. Neurosci. 2006, 26:1331-1333.
39. McCool B.A., Lovinger D.M. Ifenprodil inhibition of the 5-hydroxytryptamine3 receptor. Neuropharmacology 1995, 34:621-629.
40. von Engelhardt J., et al. Excitotoxicity in vitro by NR2A- and NR2B-containing NMDA receptors. Neuropharmacology 2007, 53:10-17.
41. Martel M.A., et al. In developing hippocampal neurons NR2B-containing N-methyl-D-aspartate receptors (NMDARs) can mediate signaling to neuronal survival and synaptic potentiation, as well as neuronal death. Neuroscience 2009, 158:334-343.
42. Harris A.Z., Pettit D.L. Extrasynaptic and synaptic NMDA receptors form stable and uniform pools in rat hippocampal slices. J. Physiol. 2007, 584:509-519.
43. Rossi D.J., et al. Glutamate release in severe brain ischaemia is mainly by reversed uptake. Nature 2000, 403:316-321.
44. Florio S.K., et al. Disruption of nNOS-PSD95 protein-protein interaction inhibits acute thermal hyperalgesia and chronic mechanical allodynia in rodents. Br. J. Pharmacol. 2009, 158:494-506.
45. Baker S.J. PTEN enters the nuclear age. Cell 2007, 128:25-28.
46. Ning K., et al. Dual neuroprotective signaling mediated by downregulating two distinct phosphatase activities of PTEN. J. Neurosci. 2004, 24:4052-4060.
47. Zhang Q.G., et al. Critical role of PTEN in the coupling between PI3K/Akt and JNK1/2 signaling in ischemic brain injury. FEBS Lett. 2007, 581:495-505.
48. Gary D.S., Mattson M.P. PTEN regulates Akt kinase activity in hippocampal neurons and increases their sensitivity to glutamate and apoptosis. Neuromol. Med. 2002, 2:261-269.
49. Liu C., et al. Neuroprotection by baicalein in ischemic brain injury involves PTEN/AKT pathway. J. Neurochem. 2010, 112:1500-1512.
50. Lee S.M., et al. The protective effect of early hypothermia on PTEN phosphorylation correlates with free radical inhibition in rat stroke. J. Cereb. Blood Flow Metab. 2009, 29:1589-1600.
51. Zhang, S. et al. (2009) PTEN nuclear translocation induced by NMDAR activation enhances neuronal death. Program No. 149.5. 2009. Neuroscience Meeting Planner. Chicago, IL: Society for Neuroscience, 2009. Online.
52. Jurado S., et al. PTEN is recruited to the postsynaptic terminal for NMDA receptor-dependent long-term depression. EMBO J. 2010, 29:2827-2840.
53. Bialik S., Kimchi A. The death-associated protein kinases: structure, function, and beyond. Annu. Rev. Biochem. 2006, 75:189-210.
54. Brorson J.R., et al. Delayed antagonism of calpain reduces excitotoxicity in cultured neurons. Stroke 1995, 26:1259-1266. (discussion 1267).
55. Koumura A., et al. A novel calpain inhibitor, ((1S)-1((((1S)-1-benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-methylbutyl) carbamic acid 5-methoxy-3-oxapentyl ester, protects neuronal cells from cerebral ischemia-induced damage in mice. Neuroscience 2008, 157:309-318.
56. Taghibiglou C., et al. Role of NMDA receptor-dependent activation of SREBP1 in excitotoxic and ischemic neuronal injuries. Nat. Med. 2009, 15:1399-1406.
57. Xu W., et al. Calpain-mediated mGluR1alpha truncation: a key step in excitotoxicity. Neuron 2007, 53:399-412.
58. Lee M.S., et al. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 2000, 405:360-364.
59. Kim M.J., et al. Differential roles of NR2A- and NR2B-containing NMDA receptors in Ras-ERK signaling and AMPA receptor trafficking. Neuron 2005, 46:745-760.
60. Tigaret C.M., et al. Subunit dependencies of N-methyl-D-aspartate (NMDA) receptor-induced alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor internalization. Mol. Pharmacol. 2006, 69:1251-1259.
61. Li Z., et al. Caspase-3 activation via mitochondria is required for long-term depression and AMPA receptor internalization. Cell 2010, 141:859-871.
62. Wang Y., et al. alpha-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid subtype glutamate receptor (AMPAR) endocytosis is essential for N-methyl-D-aspartate-induced neuronal apoptosis. J. Biol. Chem. 2004, 279:41267-41270.
63. Ahmadian G., et al. Tyrosine phosphorylation of GluR2 is required for insulin-stimulated AMPA receptor endocytosis and LTD. EMBO J. 2004, 23:1040-1050.
64. Dolph P.J. Arrestin: roles in the life and death of retinal neurons. Neuroscientist 2002, 8:347-355.
65. McDonald P.H., et al. Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science 2000, 290:1574-1577.
66. Liu S., et al. Expression of Ca(2+)-permeable AMPA receptor channels primes cell death in transient forebrain ischemia. Neuron 2004, 43:43-55.
67. Noh K.-M., et al. Blockade of calcium-permeable AMPA receptors protects hippocampal neurons against global ischemia-induced death. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:12230-12235.
68. Pearson G., et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev. 2001, 22:153-183.
69. Chen C.-H., et al. Bidirectional signals transduced by DAPK-ERK interaction promote the apoptotic effect of DAPK. EMBO 2005, 24:294-304.
70. Guo R.X., et al. NMDA receptors are involved in upstream of the spinal JNK activation in morphine antinociceptive tolerance. Neurosci. Lett. 2009, 467:95-99.
71. Cao J., et al. The PSD95-nNOS interface: a target for inhibition of excitotoxic p38 stress-activated protein kinase activation and cell death. J. Cell Biol. 2005, 168:117-126.
72. Soriano F.X., et al. Specific targeting of pro-death NMDA receptor signals with differing reliance on the NR2B PDZ ligand. J. Neurosci. 2008, 28:10696-10710.
73. Kawasaki H., et al. Activation and involvement of p38 mitogen-activated protein kinase in glutamate-induced apoptosis in rat cerebellar granule cells. J. Biol. Chem. 1997, 272:18518-18521.
74. Legos J.J., et al. The selective p38 inhibitor SB-239063 protects primary neurons from mild to moderate excitotoxic injury. Eur. J. Pharmacol. 2002, 447:37-42.
75. Barone F.C., et al. Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia. Med. Res. Rev. 2001, 21:129-145.
76. Borsello T., et al. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat. Med. 2003, 9:1180-1186.
77. Hirt L., et al. D-JNKI1, a cell-penetrating c-Jun-N-terminal kinase inhibitor, protects against cell death in severe cerebral ischemia. Stroke 2004, 35:1738-1743.
78. Esneault E., et al. D-JNKi, a peptide inhibitor of c-Jun N-terminal kinase, promotes functional recovery after transient focal cerebral ischemia in rats. Neuroscience 2008, 152:308-320.
79. Goldstein J.L., et al. Protein sensors for membrane sterols. Cell 2006, 124:35-46.
80. Adibhatla R.M., et al. Lipids and lipidomics in brain injury and diseases. AAPS J. 2006, 8:E314-321.
81. Siesjo B.K., Katsura K. Ischemic brain damage: focus on lipids and lipid mediators. Adv. Exp. Med. Biol. 1992, 318:41-56.
82. Park H.J., et al. Role of sterol regulatory element binding proteins in the regulation of Galpha(i2) expression in cultured atrial cells. Circ. Res. 2002, 91:32-37.
83. Park H.J., et al. Parasympathetic response in chick myocytes and mouse heart is controlled by SREBP. J. Clin. Invest. 2008, 118:259-271.
84. Corbett D., Nurse S. The problem of assessing effective neuroprotection in experimental cerebral ischemia. Prog. Neurobiol. 1998, 54:531-548.
85. Albers G.W., et al. Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial. JAMA 2001, 286:2673-2682.
86. Lees K.R., et al. Glycine antagonist (GV150526) in acute stroke: a multicentre, double-blind placebo-controlled phase II trial. Cerebrovasc. Dis. 2001, 11:20-29.
87. Cho K.O., et al. The rat brain postsynaptic density fraction contains a homolog of the Drosophila discs-large tumor suppressor protein. Neuron 1992, 9:929-942.
88. Eisenberg-Lerner A., Kimchi A. DAP kinase regulates JNK signaling by binding and activating protein kinase D under oxidative stress. Cell Death Differ. 2007, 14:1908-1915.